Animal study · mice

Pemvidutide cut body weight about 25% in mice with NASH

Checked against the paper Animal studyPublished by PepVault

The takeaway

In a mouse model of NASH, pemvidutide beat semaglutide and elafibranor on weight and several liver measures, but this is early animal evidence, not a human result.

Kind
Animal study
Studied in
Mice
Published
2022
Journal
Sci Rep

What they tested

The team tested how pemvidutide (ALT-801) compared with semaglutide and elafibranor on weight and liver disease in a mouse model of NASH, a fatty liver disease with inflammation.

How the study was done

A study in male C57BL/6J mice fed a NASH-inducing diet for 32 weeks, with liver fat and scarring confirmed by biopsy, a small tissue sample. They then got pemvidutide, semaglutide, elafibranor or vehicle (an inactive control) daily for 12 weeks while staying on the diet.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking pemvidutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In mice, pemvidutide reduced body weight by about 25%. It also lowered blood liver enzymes and blood total cholesterol, cut fat and cholesterol in the liver, and improved liver steatosis (fat buildup), with bigger drops than semaglutide or elafibranor (p < 0.05). It lowered galectin-3, an inflammation marker, and collagen type 1 alpha 1, a scarring marker, compared with vehicle (p < 0.05), and cut galectin-3 more than elafibranor (p < 0.05). Every mouse on pemvidutide improved its NAS, a combined score of fatty liver disease activity, compared with the active controls.

What it doesn’t show

This was a mouse study, so it doesn't show the same effects in people. It used only male mice and lasted 12 weeks of treatment.

The paper

Nestor et al. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis. Sci Rep. 2022.

The compound

More studies on Pemvidutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking pemvidutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo